[go: up one dir, main page]

BRPI0515946A - sal de tosilato, sua preparação e uso, bem como composição farmacêutica compreendendo o mesmo - Google Patents

sal de tosilato, sua preparação e uso, bem como composição farmacêutica compreendendo o mesmo

Info

Publication number
BRPI0515946A
BRPI0515946A BRPI0515946-6A BRPI0515946A BRPI0515946A BR PI0515946 A BRPI0515946 A BR PI0515946A BR PI0515946 A BRPI0515946 A BR PI0515946A BR PI0515946 A BRPI0515946 A BR PI0515946A
Authority
BR
Brazil
Prior art keywords
preparation
pharmaceutical composition
same
tosylate salt
well
Prior art date
Application number
BRPI0515946-6A
Other languages
English (en)
Inventor
Alfons Grunenberg
Jana Lenz
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35482258&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0515946(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of BRPI0515946A publication Critical patent/BRPI0515946A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Medicinal Preparation (AREA)
  • Paper (AREA)
  • Catalysts (AREA)
  • Glass Compositions (AREA)

Abstract

'SAL DE TOSILATO, SUA PREPARAçãO E USO, BEM COMO COMPOSIçãO FARMACêUTICA, COMPREENDENDO O MESMO". A presente invenção refere-se a uma nova forma termodinamicamente estável, à temperatura ambiente, do sal de tosilato de 4-{4-¢({¢4-cloro-3-(trifluorometil)fenil!amino}carbonil)amino!fenóxi}-N- metilpiridina-2-carbixamida, para processar sua preparação, para medicamentos que compreendem ele e seu uso no controle de distúrbios.
BRPI0515946-6A 2004-09-29 2005-09-20 sal de tosilato, sua preparação e uso, bem como composição farmacêutica compreendendo o mesmo BRPI0515946A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04023130 2004-09-29
PCT/EP2005/010119 WO2006034797A1 (en) 2004-09-29 2005-09-20 Thermodynamically stable form of bay 43-9006 tosylate

Publications (1)

Publication Number Publication Date
BRPI0515946A true BRPI0515946A (pt) 2008-08-12

Family

ID=35482258

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515946-6A BRPI0515946A (pt) 2004-09-29 2005-09-20 sal de tosilato, sua preparação e uso, bem como composição farmacêutica compreendendo o mesmo

Country Status (32)

Country Link
US (1) US8877933B2 (pt)
EP (1) EP1797038B1 (pt)
JP (2) JP5215666B2 (pt)
KR (4) KR101239489B1 (pt)
CN (1) CN101065360B (pt)
AR (1) AR051301A1 (pt)
AU (1) AU2005289100B2 (pt)
BR (1) BRPI0515946A (pt)
CA (1) CA2581843C (pt)
CU (1) CU20070068A7 (pt)
CY (1) CY1113598T1 (pt)
DK (1) DK1797038T3 (pt)
EC (1) ECSP077356A (pt)
ES (1) ES2387812T3 (pt)
GT (1) GT200500270A (pt)
HN (1) HN2005000722A (pt)
HR (1) HRP20120662T1 (pt)
IL (1) IL181734A (pt)
MA (1) MA28880B1 (pt)
MY (1) MY176929A (pt)
NO (1) NO344272B1 (pt)
NZ (1) NZ553804A (pt)
PE (3) PE20060699A1 (pt)
PL (1) PL1797038T3 (pt)
PT (1) PT1797038E (pt)
SG (1) SG155996A1 (pt)
SI (1) SI1797038T1 (pt)
TW (1) TWI382016B (pt)
UA (1) UA91520C2 (pt)
UY (1) UY29144A1 (pt)
WO (1) WO2006034797A1 (pt)
ZA (1) ZA200702510B (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002534468A (ja) 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
PT1478358E (pt) 2002-02-11 2013-09-11 Bayer Healthcare Llc Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal
US10653684B2 (en) 2002-02-11 2020-05-19 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
DK1636585T3 (da) 2003-05-20 2008-05-26 Bayer Pharmaceuticals Corp Diarylurinstoffer med kinasehæmmende aktivitet
PT1663978E (pt) 2003-07-23 2008-02-15 Bayer Pharmaceuticals Corp Omega-carboxiaril difenil ureia substituída por flúor para o tratamento e a prevenção de doenças e estados patológicos
UA91520C2 (en) 2004-09-29 2010-08-10 Баер Шеринг Фарма Акциенгезельшафт Thermodynamically stable form of tosylate
PT1868579E (pt) 2005-03-07 2010-12-03 Bayer Schering Pharma Ag Composição farmacêutica que compreende uma difenil-ureia substituída com um omega-carboxiarilo para o tratamento do cancro
JP2009513707A (ja) * 2005-10-31 2009-04-02 バイエル ヘルスケア リミティド ライアビリティ カンパニー ジアリールウレア及び併用剤
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
WO2008058644A1 (en) * 2006-11-14 2008-05-22 Bayer Schering Pharma Aktiengesellschaft Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
CN101220024A (zh) * 2007-12-11 2008-07-16 杜晓敏 一组抑制激酶的抗癌化合物
US8217061B2 (en) 2008-01-17 2012-07-10 Sicor Inc. Polymorphs of sorafenib tosylate and sorafenib hemi-tosylate, and processes for preparation thereof
WO2009106825A1 (en) * 2008-02-27 2009-09-03 Cipla Limited Polymorphs of sorafenib and salts thereof
WO2010079498A2 (en) * 2009-01-12 2010-07-15 Hetero Research Foundation Novel polymorph of sorafenib tosylate
AU2009344660A1 (en) * 2009-04-15 2011-11-17 Fondazione Irccs Istituto Nazionale Dei Tumori Use of multi-kinase inhibitors in the treatment of vascular hyperpermeability
EP2440531A2 (en) * 2009-06-12 2012-04-18 Ratiopharm GmbH Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-pyridine-2-carboxamide
AU2010299484A1 (en) 2009-09-24 2012-05-03 Ranbaxy Laboratories Limited Polymorphs of sorafenib acid addition salts
WO2011036647A1 (en) 2009-09-24 2011-03-31 Ranbaxy Laboratories Limited Process for the preparation of sorafenib tosylate
WO2011058522A1 (en) 2009-11-12 2011-05-19 Ranbaxy Laboratories Limited Sorafenib ethylsulfonate salt, process for preparation and use
WO2011076711A2 (en) 2009-12-23 2011-06-30 Ratiopharm Gmbh Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide
US8618305B2 (en) 2010-01-29 2013-12-31 Ranbaxy Laboratories Limited Sorafenib dimethyl sulphoxide solvate
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
PE20140165A1 (es) 2010-10-01 2014-02-26 Bayer Ip Gmbh Combinaciones que contienen n-(2-arilamino)arilsulfonamida
WO2012071425A1 (en) 2010-11-22 2012-05-31 Teva Pharmaceutical Industries Ltd. Solid state forms of sorafenib besylate, and processes for preparations thereof
CN103764118A (zh) 2011-06-28 2014-04-30 拜尔健康护理有限责任公司 含有索拉非尼的局部眼用药用组合物
EP2559431A1 (en) 2011-08-17 2013-02-20 Ratiopharm GmbH Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
EP2806860B1 (en) 2012-01-23 2023-04-19 Sandoz AG Pharmaceutical composition containing crystalline sorafenib tosylate
WO2013175506A2 (en) 2012-05-21 2013-11-28 Hetero Research Foundation Process for sorafenib tosylate polymorph iii
AU2012380672B2 (en) * 2012-05-23 2015-05-14 Shilpa Medicare Limited Process for preparing crystalline Sorafenib tosylate
CN103570613B (zh) * 2012-07-18 2016-06-15 苏州泽璟生物制药有限公司 氘代ω-二苯基脲或其盐的多晶型物
CN103896833B (zh) * 2012-12-27 2016-12-28 上海创诺制药有限公司 索拉非尼对甲苯磺酸盐溶剂化物多晶型物及其制法和用途
WO2014118807A1 (en) * 2013-02-04 2014-08-07 Intas Pharmaceuticals Limited A novel process for the preparation of sorafenib tosylate form iii
WO2014138905A1 (en) * 2013-03-14 2014-09-18 Apotex Technologies Inc. Forms of sorafenib tosylate and processes for the preparation thereof
DE112014002349B4 (de) 2013-05-10 2019-12-05 Denso Corporation Kraftstoffeinspritzsteuervorrichtung und Kraftstoffeinspritzsystem
CN104761492A (zh) * 2014-01-03 2015-07-08 正大天晴药业集团股份有限公司 对甲苯磺酸索拉非尼的晶型及其制备方法
WO2015196072A2 (en) * 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
CN104177292A (zh) * 2014-08-08 2014-12-03 亿腾药业（泰州）有限公司 一种工业化生产甲苯磺酸索拉非尼多晶型ⅰ的方法
CN105439947A (zh) * 2014-12-01 2016-03-30 石药集团中奇制药技术（石家庄）有限公司 一种甲苯磺酸索拉非尼新晶型及其制备方法
RU2568638C1 (ru) * 2015-02-26 2015-11-20 Индивидуальный предприниматель Михайлов Олег Ростиславович КРИСТАЛЛИЧЕСКАЯ β-МОДИФИКАЦИЯ 4-[4-({ [4-ХЛОРО-3-(ТРИФТОРОМЕТИЛ) ФЕНИЛ]КАРБАМОИЛ} АМИНО)ФЕНОКСИ]-N-МЕТИЛ-ПИРИДИН-2-КАРБОКСАМИДА п-ТОЛУОЛСУЛЬФОНАТА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЁ ОСНОВЕ
EP3109236B1 (en) 2015-06-23 2017-08-09 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Scalable process for the preparation of sorafenib tosylate ethanol solvate and sorafenib tosylate form iii
CN106336377A (zh) * 2015-07-17 2017-01-18 苏州亚宝药物研发有限公司 一种甲苯磺酸索拉非尼晶型ⅱ的制备方法
CN105503715A (zh) * 2015-12-03 2016-04-20 神威药业集团有限公司 一种索拉非尼半甲苯磺酸盐多晶型及其制备方法
CN105585523A (zh) * 2015-12-29 2016-05-18 上海北卡医药技术有限公司 一种对甲苯磺酸索拉非尼的新晶型及其制备方法和用途
CN107759517A (zh) * 2016-08-23 2018-03-06 广州白云山医药集团股份有限公司白云山制药总厂 一种甲苯磺酸索拉非尼晶型ⅰ的制备方法
CN107840823B (zh) * 2016-09-20 2021-08-17 意大利合成制造有限公司 用于制备甲苯磺酸索拉非尼乙醇溶剂化物和iii型甲苯磺酸索拉非尼的可变规模的方法
CN108164459B (zh) * 2016-12-07 2021-07-27 上海创诺制药有限公司 甲苯磺酸索拉非尼晶型iii的制备方法
JP7481115B2 (ja) 2017-01-05 2024-05-10 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形性形態
CN109796400B (zh) * 2017-11-16 2022-07-29 四川科伦药物研究院有限公司 一种甲苯磺酸索拉菲尼晶型及其制备方法
US11179322B2 (en) 2018-07-10 2021-11-23 Novocure Gmbh Methods and compositions for treating tumors with TTFields and sorafenib
WO2018211336A2 (en) 2018-09-07 2018-11-22 Alvogen Malta Operations (Row) Ltd Solid dosage form containing sorafenib tosylate
CN113677346A (zh) 2018-11-01 2021-11-19 希洛斯医药品股份有限公司 周期蛋白依赖性激酶7(cdk7)的抑制剂
CN110156671A (zh) * 2019-06-06 2019-08-23 杭州中美华东制药有限公司 新型的索拉非尼共晶及其制备方法
EP4007585A4 (en) 2019-08-02 2023-11-08 OneHealthCompany, Inc. TREATMENT OF CANINE CANCERS
KR102887639B1 (ko) * 2019-10-25 2025-11-18 한미약품 주식회사 생산성 및 용출성이 개선된 소라페닙 토실레이트염의 제제 및 그 제조 방법
CN117088809A (zh) * 2022-05-12 2023-11-21 浙江工业大学 一种索拉非尼-丙二酸共晶及其制备方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629425A (en) * 1994-09-19 1997-05-13 Eli Lilly And Company Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
CO4410190A1 (es) 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
WO1997046526A1 (en) * 1996-06-07 1997-12-11 Eisai Co., Ltd. Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
EA001881B1 (ru) 1996-09-23 2001-10-22 Эли Лилли Энд Компани Форма d дигидрата оланзапина
US6187799B1 (en) * 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US6344476B1 (en) * 1997-05-23 2002-02-05 Bayer Corporation Inhibition of p38 kinase activity by aryl ureas
US7329670B1 (en) * 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US7517880B2 (en) * 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2002534468A (ja) 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
US8124630B2 (en) * 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ME00275B (me) * 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US7235576B1 (en) * 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
RU2316326C2 (ru) * 2001-12-03 2008-02-10 Байер Фамэсьютиклс Копэрейшн Способ и композиция для лечения ракового заболевания, тозилат и фармацевтически приемлемые соли n-(4-хлор-3-(трифторметил)фенил)-n'-(4-(2-(n-метилкарбамоил)-4-пиридилокси)фенил)мочевины
GB0129876D0 (en) 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
US20030207872A1 (en) * 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
PT1580188E (pt) * 2002-02-11 2012-01-25 Bayer Healthcare Llc Aril-ureias como inibidores de cinases
PT1478358E (pt) * 2002-02-11 2013-09-11 Bayer Healthcare Llc Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal
US20030216396A1 (en) * 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
GB0203412D0 (en) 2002-02-13 2002-04-03 Pharmagene Lab Ltd 5-HT 2B receptor antagonists
US6965550B2 (en) 2002-03-29 2005-11-15 Sony Corporation Optical disk identifying device, optical disk identifying method, optical disk recorder, and optical disk reproducing device
AU2003222310B2 (en) * 2002-05-03 2009-04-09 Janssen Pharmaceutica N.V. Polymeric microemulsions
US7351534B2 (en) * 2003-01-27 2008-04-01 Oregon Health & Sciences University Gene mutation associated with age-related macular degeneration
UY28213A1 (es) * 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
US7378233B2 (en) * 2003-04-12 2008-05-27 The Johns Hopkins University BRAF mutation T1796A in thyroid cancers
DK1636585T3 (da) * 2003-05-20 2008-05-26 Bayer Pharmaceuticals Corp Diarylurinstoffer med kinasehæmmende aktivitet
PT1663978E (pt) * 2003-07-23 2008-02-15 Bayer Pharmaceuticals Corp Omega-carboxiaril difenil ureia substituída por flúor para o tratamento e a prevenção de doenças e estados patológicos
MXPA06012394A (es) * 2004-04-30 2007-01-31 Bayer Pharmaceuticals Corp Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer.
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
MX2007002398A (es) * 2004-08-27 2007-05-15 Bayer Pharmaceuticals Corp Nuevas composiciones farmaceuticas para el tratamiento de cancer.
UA91520C2 (en) 2004-09-29 2010-08-10 Баер Шеринг Фарма Акциенгезельшафт Thermodynamically stable form of tosylate
ES2532377T3 (es) * 2004-09-29 2015-03-26 Bayer Healthcare Llc Procedimiento de preparación de 4-{4-[({[4-[cloro-3-(trifluorometil)fenil]amino}carbonil) amino]fenoxi}N-metilpiridina-2-carboxamida
US7271763B2 (en) * 2005-03-03 2007-09-18 The United States Of America As Represented By The Secretary Of The Army Hybrid-phased communication array
PT1868579E (pt) 2005-03-07 2010-12-03 Bayer Schering Pharma Ag Composição farmacêutica que compreende uma difenil-ureia substituída com um omega-carboxiarilo para o tratamento do cancro
US20090215835A1 (en) * 2005-10-31 2009-08-27 Scott Wilhelm Treatment of cancer with sorafenib
US8329408B2 (en) * 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
US20100035888A1 (en) * 2005-11-10 2010-02-11 Bater Healthcare AG Diaryl Urea for Treating Pulmonary Hypertension
WO2007059154A2 (en) * 2005-11-14 2007-05-24 Bayer Healthcare Llc Treatment of cancers with acquired resistance to kit inhibitors
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
CA2668748A1 (en) * 2006-11-09 2008-05-15 Bayer Schering Pharma Aktiengesellschaft Polymorph iii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
WO2008058644A1 (en) * 2006-11-14 2008-05-22 Bayer Schering Pharma Aktiengesellschaft Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
WO2008079968A1 (en) * 2006-12-20 2008-07-03 Bayer Healthcare Llc 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl) phenyl]-1h-pyrazol-5-yl } carbamoyl)-amino] -3-fluorophenoxy} -n-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer
EP2114403A2 (en) * 2007-01-19 2009-11-11 Bayer Healthcare, LLC Treatment of cancers having resistance to chemotherapeutic agents
WO2008089389A2 (en) * 2007-01-19 2008-07-24 Bayer Healthcare Llc Treatment of cancers with acquired resistance to kit inhibitors
US8217061B2 (en) * 2008-01-17 2012-07-10 Sicor Inc. Polymorphs of sorafenib tosylate and sorafenib hemi-tosylate, and processes for preparation thereof
JP5439494B2 (ja) * 2008-10-21 2014-03-12 バイエル ヘルスケア エルエルシー 肝細胞癌と関連するシグネチャ遺伝子の同定
AR081060A1 (es) * 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
US20130183268A1 (en) * 2010-07-19 2013-07-18 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
PE20140165A1 (es) * 2010-10-01 2014-02-26 Bayer Ip Gmbh Combinaciones que contienen n-(2-arilamino)arilsulfonamida
AP2013007335A0 (en) 2011-06-28 2013-12-31 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing regorafenib
CN103764118A (zh) 2011-06-28 2014-04-30 拜尔健康护理有限责任公司 含有索拉非尼的局部眼用药用组合物

Also Published As

Publication number Publication date
MA28880B1 (fr) 2007-09-03
UY29144A1 (es) 2006-04-28
PE20100445A1 (es) 2010-07-04
KR20090018224A (ko) 2009-02-19
ES2387812T3 (es) 2012-10-02
PE20142042A1 (es) 2014-12-03
IL181734A0 (en) 2007-07-04
KR20130004385A (ko) 2013-01-09
CA2581843A1 (en) 2006-04-06
CN101065360A (zh) 2007-10-31
CU20070068A7 (es) 2010-01-22
AU2005289100A1 (en) 2006-04-06
GT200500270A (es) 2006-04-25
CN101065360B (zh) 2011-08-03
US20090215833A1 (en) 2009-08-27
JP5215666B2 (ja) 2013-06-19
NO344272B1 (no) 2019-10-21
DK1797038T3 (da) 2012-09-03
US8877933B2 (en) 2014-11-04
ZA200702510B (en) 2008-07-30
PL1797038T3 (pl) 2012-11-30
CY1113598T1 (el) 2016-06-22
EP1797038B1 (en) 2012-06-13
PT1797038E (pt) 2012-08-14
UA91520C2 (en) 2010-08-10
TWI382016B (zh) 2013-01-11
MY176929A (en) 2020-08-27
PE20060699A1 (es) 2006-08-12
HK1114605A1 (en) 2008-11-07
HRP20120662T1 (hr) 2012-09-30
KR20100061869A (ko) 2010-06-09
NZ553804A (en) 2010-07-30
CA2581843C (en) 2012-05-15
KR20070058537A (ko) 2007-06-08
SG155996A1 (en) 2009-10-29
JP2008514658A (ja) 2008-05-08
TW200626552A (en) 2006-08-01
HN2005000722A (es) 2010-08-19
AU2005289100B2 (en) 2011-11-03
WO2006034797A1 (en) 2006-04-06
KR101381454B1 (ko) 2014-04-04
SI1797038T1 (sl) 2012-10-30
IL181734A (en) 2015-10-29
NO20071508L (no) 2007-06-22
KR101239489B1 (ko) 2013-03-06
EP1797038A1 (en) 2007-06-20
AR051301A1 (es) 2007-01-03
ECSP077356A (es) 2007-04-26
JP2013100302A (ja) 2013-05-23

Similar Documents

Publication Publication Date Title
BRPI0515946A (pt) sal de tosilato, sua preparação e uso, bem como composição farmacêutica compreendendo o mesmo
CU20070069A7 (es) Proceso para la preparación de 4-{4-[cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida
AR045317A1 (es) Forma cristalina de agonista dl receptor adrenergico b2
BRPI0413849A (pt) metanossulfonato de etiléster de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamin o]-metil}-1-metil-1h-benzimidazol-5-carbonil)-piridin-2 -il-amino]-propiÈnico e seu uso como medicamento
MX338338B (es) Composiciones y metodos utiles para el tratamiento de enfermedades respiratorias.
PT998473E (pt) Modificacao da forma de cristal de um derivado de n-fenil-2-pirimidinoamina processos para a sua preparacao e sua utilizacao
UA95984C2 (en) 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl)]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide monohydrate
BR0015048A (pt) Sal farmacêutico, medicamento, uso de pelo menos um sal de tramadol e formas de apresentação
PE20050255A1 (es) Nuevas cianotiazolidas y procedimiento para su preparacion como medicamentos
BR112014027244A2 (pt) derivados de benzamida para inibição da atividade de abl1, abl2 e bcr-abl1
SE0301010D0 (sv) Novel compounds
SE0301009D0 (sv) Novel compounds
BRPI0409916A (pt) ácidos carboxìlicos substituìdos com fenila
HN2002000319A (es) Benzamida, heteroarilamida y amidas inversas
BR112013025881A2 (pt) composto representado pela fórmula geral (i), composto ou um sal do mesmo, inibidor deagregação tau, inibidor de b-secretase, inibidor de agregação de b-proteína amiloide, composição farmacêutica, preparação oral ou parenteral e composto representado pela fórmula geral (ii)
EA200801769A1 (ru) Тригидрохлориды производного дигидроптеридинона и способы их получения
HRP20050843A2 (en) Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use of the same as medicaments, and medicament containing such compounds
BRPI0515429A (pt) novas amidas heterocìclicas
BR0317834A (pt) Diamidas de ácido pirimidin-4,6-dicarboxìlico como inibidores mmp 13 seletivos
PA8800401A1 (es) Productos quimioterapeuticos cristalinos
CL2007003216A1 (es) Sal de 2(s), 4(s), 5(s), 7(s)-n-(3-amino-2,2-dimetil-3-oxo-propil)2,7-di(1-metil-etil)-4-hidroxi-5-amino-8-[4-metoxi-3-(3-metoxi-propoxi)fenil]-octanamida; proceso de preparacion; composicion farmaceutica; y uso para la profilaxis o tratamiento de en
DOP2005000184A (es) Forma termodinamicamente estable de una sal tosilato
BR0207867A (pt) Sal de benzoilguanidina
BRPI0407199A (pt) (benzoimidazol-2-il)-fenil-aminas n-substituìdas, processo para a sua preparação, sua aplicação como medicamento ou diagnóstico bem como o medicamento contendo as mesmas
TH98396A (th) 4-[4-({[4-คลอโร-3-(ไตรฟลูออโรเมทธิล)ฟีนิล]คาร์บาโมอิล}อะมิโน)-3-ฟลูออโรฟีนอกซี]-n-เมทธิลไพริดีน-2-คาร์บอกซาไมด์ โมโนไฮเดรท

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE)

Free format text: TRANSFERIDO POR FUSAO DE: BAYER HEALTHCARE AG

B25D Requested change of name of applicant approved

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT (DE)

B25A Requested transfer of rights approved

Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE)

B25A Requested transfer of rights approved

Owner name: BAYER HEALTHCARE LLC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]